文献速递血脂与心血管预防冠心病

GOULD注册研究:美国ASCVD患者2年降脂治疗模式

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.
PubMed 文献 · JAMA Cardiol · 2021-01-01

GOULD是一项多中心前瞻性观察性注册研究,纳入5006例接受降脂治疗的ASCVD患者,分为PCSK9i组、LDL-C≥100 mg/dL组和LDL-C 70-99 mg/dL组,随访2年。结果显示仅17.1%患者降脂治疗强化,三分之二患者LDL-C仍高于70 mg/dL;教学医院、有血脂管理方案及心内科管理者的强化治疗率和LDL-C达标率更高。

要点

  • ASCVD患者2年内仅17.1%强化降脂治疗,多数LDL-C未达标。
  • 教学医院、有血脂方案及心内科管理可提高强化治疗和LDL-C达标率。
  • PCSK9i组91.7%持续用药,但仅52.4%达到LDL-C<70 mg/dL。

核心结论

  • ASCVD患者中多数基线LDL-C不理想,2年后仅17.1%强化降脂治疗,三分之二LDL-C仍>70 mg/dL,需加强管理。

研究设计与样本

  • GOULD为多中心前瞻性观察性注册研究,2016年12月至2018年7月纳入5006例接受降脂治疗的ASCVD患者,随访2年。

主要发现

  • 2年时885例(17.1%)强化降脂治疗;LDL-C≥100 mg/dL组和70-99 mg/dL组强化率分别为22.4%和14.4%。
  • PCSK9i组554例中508例(91.7%)2年时仍在用药。
  • LDL-C<70 mg/dL达标率:LDL-C≥100 mg/dL组21.0%,70-99 mg/dL组33.9%,PCSK9i组52.4%。

关键数值与推荐

  • LDL-C中位数变化:≥100 mg/dL组从120 mg/dL降至95 mg/dL,70-99 mg/dL组从82 mg/dL降至77 mg/dL,PCSK9i组维持67 mg/dL。

临床怎么用

  • 教学医院、有血脂管理方案及心内科管理可提高降脂强化率和LDL-C<70 mg/dL达标率(P<.001或P=.003)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) recommend intensive statin therapy and adding nonstatin therapy if low-density lipoprotein cholesterol (LDL-C) levels are 70 mg/dL or more. Compliance with guidelines is often low. OBJECTIVE: To track LDL-C treatment patterns in the US over 2 years. DESIGN, SETTING, AND PARTICIPANTS: GOULD is a prospective observational registry study involving multiple centers. Patients with ASCVD receiving any lipid-lowering therapy (LLT) were eligible. Between December 2016 and July 2018, patients were enrolled in 1 of 3 cohorts: (1) those currently receiving proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) and 2 groups not receiving PCSK9i drugs, with (2) LDL-C levels of 100 mg/dL or more or (3) LDL-C levels of 70 to 99 mg/dL. Patients had medical record reviews and telephone interviews every 6 months. Analysis was done on data collected as of October 5, 2020. MAIN OUTCOMES AND MEASURES: The primary outcome was the change in LLT use in 2 years. Secondary outcomes included the number of LDL-C measurements, LDL-C levels, and responses to structured physician and patient questionnaires over 2 years. RESULTS: A total of 5006 patients were enrolled (mean [SD] age, 67.8 [9.9] years; 1985 women [39.7%]; 4312 White individuals [86.1%]). At 2 years, 885 (17.1%) had LLT intensification. In the cohorts with LDL-C levels of 100 mg/dL or more and 70 to 99 mg/dL, LLT intensification occurred in 403 (22.4%) and 383 (14.4%), respectively; statins were intensified in 115 (6.4%) and 168 (6.3%), ezetimibe added in 123 (6.8%) and 118 (4.5%), and PCSK9i added in 114 (6.3%) and 58 (2.2%), respectively. In the PCSK9i cohort, 508 of 554 (91.7%) were still taking PCSK9i at 2 years. Lipid panels were measured at least once over 2 years in 3768 patients (88.5%; PCSK9i cohort, 492 [96.1%]; LDL-C levels ≥100 mg/dL or more, 1294 [85.9%]; 70-99 mg/dL, 1982 [88.6%]). Levels of LDL-C fell from medians (interquartile ranges) of 120 (108-141) mg/dL to 95 (73-118) mg/dL in the cohort with LDL-C levels of 100 mg/dL or more, 82 (75-89) to 77 (65-90) mg/dL in the cohort with LDL-C levels of 70 to 99 mg/dL, and 67 (42-104) mg/dL to 67 (42-96) mg/dL in the PCSK9i cohort. Levels of LDL-C less than 70 mg/dL at 2 years were achieved by 308 patients (21.0%) and 758 patients (33.9%) in the cohorts with LDL-C levels of 100 mg/dL or more and 70 to 99 mg/dL, respectively, and 272 patients (52.4%) in the PCSK9i cohort. At 2 years, practice characteristics were associated with more LLT intensification (teaching vs nonteaching hospitals, 148 of 589 [25.1%] vs 600 of 3607 [16.6%]; lipid protocols or none, 359 of 1612 [22.3%] vs 389 of 2584 [15.1%]; cardiology, 452 of 2087 [21.7%] vs internal or family medicine, 204 of 1745 [11.7%] and other, 92 of 364 [25.3%]; all P < .001) and achievement of LDL-C less than 70 mg/dL (teaching vs nonteaching hospitals, 173 of 488 [35.5%] vs 823 of 2986 [27.6%]; lipid protocols vs none, 451 of 1411 [32.0%] vs 545 of 2063 [26.4%]; both P < .001; cardiology, 523 of 1686 [30.1%] vs internal or family medicine, 377 of 1472 [25.6%] and other, 96 of 316 [30.4%]; P = .003). CONCLUSIONS AND RELEVANCE: Of patients with ASCVD, most with suboptimal LDL-C levels at baseline, only 17.1% had LLT intensification after 2 years, and two-thirds remained at an LDL-C level greater than 70 mg/dL. Further intensive efforts are needed to achieve optimal LDL-C management in patients with ASCVD.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Cannon CP, de Lemos JA, Rosenson RS, et al. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021. PMID: 34132735. doi:10.1001/jamacardio.2021.1810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。